JP2021505535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505535A5 JP2021505535A5 JP2020526625A JP2020526625A JP2021505535A5 JP 2021505535 A5 JP2021505535 A5 JP 2021505535A5 JP 2020526625 A JP2020526625 A JP 2020526625A JP 2020526625 A JP2020526625 A JP 2020526625A JP 2021505535 A5 JP2021505535 A5 JP 2021505535A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vegf receptor
- chimeric molecule
- composition according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023135127A JP2023159323A (ja) | 2017-11-30 | 2023-08-23 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025013470A JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593033P | 2017-11-30 | 2017-11-30 | |
| US62/593,033 | 2017-11-30 | ||
| US201862644425P | 2018-03-17 | 2018-03-17 | |
| US62/644,425 | 2018-03-17 | ||
| US201862748782P | 2018-10-22 | 2018-10-22 | |
| US62/748,782 | 2018-10-22 | ||
| PCT/US2018/063025 WO2019108770A1 (en) | 2017-11-30 | 2018-11-29 | Use of a vegf antagonist to treat angiogenic eye disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135127A Division JP2023159323A (ja) | 2017-11-30 | 2023-08-23 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505535A JP2021505535A (ja) | 2021-02-18 |
| JP2021505535A5 true JP2021505535A5 (https=) | 2022-01-06 |
| JP7339248B2 JP7339248B2 (ja) | 2023-09-05 |
Family
ID=64755724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526625A Active JP7339248B2 (ja) | 2017-11-30 | 2018-11-29 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023135127A Pending JP2023159323A (ja) | 2017-11-30 | 2023-08-23 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025013470A Pending JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023135127A Pending JP2023159323A (ja) | 2017-11-30 | 2023-08-23 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025013470A Pending JP2025069279A (ja) | 2017-11-30 | 2025-01-30 | 血管形成眼障害を処置するためのｖｅｇｆアンタゴニストの使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10973879B2 (https=) |
| EP (4) | EP4122486A1 (https=) |
| JP (3) | JP7339248B2 (https=) |
| KR (2) | KR20200093621A (https=) |
| CN (1) | CN111465407A (https=) |
| AU (2) | AU2018375398C1 (https=) |
| BR (1) | BR112020010659A2 (https=) |
| CA (1) | CA3083611A1 (https=) |
| DK (1) | DK3716992T3 (https=) |
| ES (1) | ES2927049T3 (https=) |
| HR (1) | HRP20221335T1 (https=) |
| HU (1) | HUE059827T2 (https=) |
| IL (3) | IL312323B1 (https=) |
| LT (1) | LT3716992T (https=) |
| MX (1) | MX2020005166A (https=) |
| MY (1) | MY201127A (https=) |
| NZ (1) | NZ764953A (https=) |
| PL (1) | PL3716992T3 (https=) |
| PT (1) | PT3716992T (https=) |
| RS (1) | RS63703B1 (https=) |
| SG (1) | SG11202004268PA (https=) |
| SI (1) | SI3716992T1 (https=) |
| SM (1) | SMT202200374T1 (https=) |
| WO (1) | WO2019108770A1 (https=) |
| ZA (1) | ZA202002821B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| WO2017096031A1 (en) | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| US10975169B1 (en) * | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| US11944663B2 (en) * | 2020-06-18 | 2024-04-02 | Chengdu Kanghong Biotechnologies Co. Ltd. | Method for treating angiogenic eye disorders using VEGF antagonists |
| WO2022120168A1 (en) * | 2020-12-04 | 2022-06-09 | Genentech, Inc. | Automated screening for diabetic retinopathy severity using color fundus image data |
| AU2022251523A1 (en) * | 2021-03-31 | 2023-09-28 | Hangzhou Exegenesis Bio Ltd. | Fusion molecules targeting vegf and angiopoietin and uses thereof |
| KR20240008821A (ko) * | 2021-05-17 | 2024-01-19 | 리제너론 파아마슈티컬스, 인크. | 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법 |
| IL315347A (en) * | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN120060370A (zh) * | 2023-11-29 | 2025-05-30 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| CA2262817A1 (en) | 1996-08-19 | 1998-02-26 | James Robl | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| JP2005511576A (ja) | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| AU2003226349B2 (en) | 2002-04-11 | 2008-01-31 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| WO2004072320A2 (en) | 2003-02-07 | 2004-08-26 | Pavco, Inc. | Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths |
| WO2004087206A2 (en) | 2003-03-28 | 2004-10-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking vegf-mediated activity |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| EP1732947B1 (en) | 2004-03-05 | 2011-04-27 | Vegenics Pty Ltd | Growth factor binding constructs materials and methods |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
| CA2567686A1 (en) | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for the treatment of human cancer |
| MXPA06014689A (es) | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| AU2005267741A1 (en) | 2004-07-30 | 2006-02-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| CA2615636A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CN103212075B (zh) | 2012-01-19 | 2017-06-27 | 成都康弘生物科技有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| EP3010526A1 (en) * | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating macular edema |
| DK4374873T3 (da) * | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| MX368442B (es) | 2014-01-25 | 2019-10-02 | Chengdu Kanghong Biotechnologies Co Ltd | Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma. |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CA2989270A1 (en) | 2015-06-16 | 2016-12-22 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
| PE20181363A1 (es) | 2015-09-23 | 2018-08-27 | Genentech Inc | Variantes optimizadas de anticuerpos anti-vegf |
| EP3377100B1 (en) * | 2015-11-18 | 2025-02-26 | Formycon AG | Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist |
| EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| DE102017210134A1 (de) | 2016-12-15 | 2018-06-21 | Fresenius Medical Care Deutschland Gmbh | System zur extrakorporalen Blutbehandlung, Behandlungsvorrichtung, Kit und Verfahren zum Betreiben eines Systems zur extrakorporalen Blutbehandlung |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
-
2018
- 2018-11-29 HU HUE18825837A patent/HUE059827T2/hu unknown
- 2018-11-29 EP EP22181390.0A patent/EP4122486A1/en not_active Withdrawn
- 2018-11-29 CA CA3083611A patent/CA3083611A1/en active Pending
- 2018-11-29 SI SI201830749T patent/SI3716992T1/sl unknown
- 2018-11-29 SG SG11202004268PA patent/SG11202004268PA/en unknown
- 2018-11-29 US US16/204,262 patent/US10973879B2/en active Active
- 2018-11-29 LT LTEPPCT/US2018/063025T patent/LT3716992T/lt unknown
- 2018-11-29 MX MX2020005166A patent/MX2020005166A/es unknown
- 2018-11-29 PL PL18825837.0T patent/PL3716992T3/pl unknown
- 2018-11-29 KR KR1020207018642A patent/KR20200093621A/ko not_active Ceased
- 2018-11-29 IL IL312323A patent/IL312323B1/en unknown
- 2018-11-29 JP JP2020526625A patent/JP7339248B2/ja active Active
- 2018-11-29 WO PCT/US2018/063025 patent/WO2019108770A1/en not_active Ceased
- 2018-11-29 SM SM20220374T patent/SMT202200374T1/it unknown
- 2018-11-29 IL IL326641A patent/IL326641A/en unknown
- 2018-11-29 MY MYPI2020002624A patent/MY201127A/en unknown
- 2018-11-29 EP EP25172993.5A patent/EP4609914A3/en active Pending
- 2018-11-29 ES ES18825837T patent/ES2927049T3/es active Active
- 2018-11-29 EP EP23187537.8A patent/EP4279135A3/en active Pending
- 2018-11-29 HR HRP20221335TT patent/HRP20221335T1/hr unknown
- 2018-11-29 IL IL274711A patent/IL274711B2/en unknown
- 2018-11-29 PT PT188258370T patent/PT3716992T/pt unknown
- 2018-11-29 DK DK18825837.0T patent/DK3716992T3/da active
- 2018-11-29 CN CN201880077100.0A patent/CN111465407A/zh active Pending
- 2018-11-29 AU AU2018375398A patent/AU2018375398C1/en active Active
- 2018-11-29 EP EP18825837.0A patent/EP3716992B1/en active Active
- 2018-11-29 RS RS20221003A patent/RS63703B1/sr unknown
- 2018-11-29 BR BR112020010659-3A patent/BR112020010659A2/pt unknown
- 2018-11-29 NZ NZ764953A patent/NZ764953A/en unknown
- 2018-11-29 KR KR1020247015825A patent/KR20240074890A/ko active Pending
-
2020
- 2020-05-15 ZA ZA2020/02821A patent/ZA202002821B/en unknown
-
2021
- 2021-01-13 US US17/148,039 patent/US12280093B2/en active Active
-
2023
- 2023-08-23 JP JP2023135127A patent/JP2023159323A/ja active Pending
-
2025
- 2025-01-17 US US19/027,504 patent/US20250268983A1/en active Pending
- 2025-01-30 JP JP2025013470A patent/JP2025069279A/ja active Pending
- 2025-02-19 AU AU2025201179A patent/AU2025201179A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505535A5 (https=) | ||
| JP2023159323A5 (https=) | ||
| IL274711B1 (en) | Use of VEGF antagonist to treat angiogenic eye disorders | |
| JP2025169389A (ja) | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 | |
| Lally et al. | Vascular endothelial growth factor and diabetic macular edema | |
| JP2024519629A (ja) | 血管新生性眼疾患の治療のための長期の高用量ｖｅｇｆアンタゴニストレジメン | |
| JP2024519629A5 (https=) | ||
| Solaiman et al. | Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema | |
| Hirano et al. | Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema | |
| KR20220062279A (ko) | 안질환의 치료 방법 | |
| Barakat et al. | Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept | |
| Kim | Exploring neovascular age-related macular degeneration and diabetic macular edema and advances in treatment. | |
| Hahn et al. | Ultra-widefield Imaging of Duchenne Muscular Dystrophy–associated Proliferative Retinal Vasculopathy Improved With Panretinal Laser Photocoagulation Alone | |
| Unsal et al. | The results of aflibercept therapy as a first line treatment of age-related macular degeneration | |
| Al-Moujahed et al. | Reperfusion of retinal ischemia in retinal occlusive vasculitis with nicotinic acid and infliximab in Adamantiades-Behçet's disease | |
| WO2025036488A9 (en) | Methods of treating age-related macular degeneration and diabetic macular edema | |
| EP4429693B1 (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| Lin | Faricimab in neovascular age-related macular degeneration: 48-week results by dosing interval cohort in the phase 3 TENAYA/LUCERNE Trials | |
| US20250339491A1 (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| Sanfilippo et al. | Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice | |
| Khandelwal et al. | Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview | |
| Weng et al. | Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy | |
| AU2024272228A1 (en) | Annexin a5 protein as a combination therapy with an anti-vegf agent for use in the treatment of macular oedema or retinal vein occlusion | |
| Hanson et al. | Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema | |
| Lie et al. | Efficacy and safety of post-scleral injection of triamcinolone acetonide for macular edema in branch retinal vein occlusion: 3 month results from a prospective randomized, controlled and open label clinical trial |